02/12/2024
Last week we announced the decision to end Synpheny-3, our pivotal study in phenylketonuria (PKU), and that as a result, Synlogic will be evaluating strategic options for the company and ceasing operations (see below press release).
We express our sincere appreciation to everyone who has worked for and with Synlogic, as we have advanced science, while building a special company and place to work.
We extend particular gratitude to the PKU & HCU communities, who inspired us, and whose partnership enabled our pursuit of a shared aspiration to bring forward a meaningful new class of medicines. For more information, please read: https://loom.ly/FZtxgso